Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Payables: 2010-2024

Historic Payables for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $2.2 million.

  • OptimizeRx's Payables fell 2603.49% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 2603.49%. This contributed to the annual value of $2.2 million for FY2024, which is 318.81% down from last year.
  • Per OptimizeRx's latest filing, its Payables stood at $2.2 million for FY2024, which was down 318.81% from $2.2 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Payables registered a high of $2.2 million during FY2023, and its lowest value of $606808.0 during FY2021.
  • For the 5-year period, OptimizeRx's Payables averaged around $1.4 million, with its median value being $1.5 million (2022).
  • Per our database at Business Quant, OptimizeRx's Payables soared by 15543.15% in 2022 and then crashed by 318.81% in 2024.
  • OptimizeRx's Payables (Annual) stood at $618250.0 in 2020, then decreased by 1.85% to $606808.0 in 2021, then skyrocketed by 155.43% to $1.5 million in 2022, then soared by 43.68% to $2.2 million in 2023, then dropped by 3.19% to $2.2 million in 2024.
  • Its Payables stands at $2.2 million for FY2024, versus $2.2 million for FY2023 and $1.5 million for FY2022.